Lv1
16 积分 2023-07-14 加入
JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1G2032R resistance mutation in NSCLC: The first-in-human phase 1 trial
6天前
已完结
Abstract 7095: QLS1403, a novel and potent PARG inhibitor with robust anti-tumor efficacy in homologous recombination deficient cancer models
6天前
已完结
PCC0208057 as a small molecule inhibitor of TRPC6 in the treatment of prostate cancer
4个月前
已完结
TRPC6 inhibition by Z3571: A structure-based strategy to ameliorate glomerular and tubular dysfunction in chronic kidney disease
4个月前
已完结
NO- and Heme-Independent sGC Activators, Runcaciguat and Nurandociguat, as New Treatment Options for CKD: From Bench to Bedside
5个月前
已关闭
First-in-class versus best-in-class: an update for new market dynamics
5个月前
已完结
First-in-Human Study of SK-08, a Novel Soluble Guanylyl Cyclase Activator: Safety, Pharmacokinetics, Pharmacodynamics, and Therapeutic Potential for CKD
7个月前
已关闭
Accelerated Discovery of Macrocyclic CDK2 Inhibitor QR-6401 by Generative Models and Structure-Based Drug Design
7个月前
已完结
Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor
7个月前
已完结
Discovery of Atirmociclib (PF-07220060): A Potent and Selective CDK4 Inhibitor
7个月前
已完结
皖公网安备34019202002308
